34. 神経線維腫症 [臨床試験数:120,薬物数:182(DrugBank:72),標的遺伝子数:84,標的パスウェイ数:194

Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-19499915/10/201914/10/2019BeatNF2 trialA Randomized Double-blind Multicenter trial to Assess the Efficacy and Safety of Bevacizumab for Neurofibromatosis Type 2 Neurofibromatosis type 2Intervention name : Bevacizumab (Genitical Recombination)
INN of the intervention : Bevacizumab (Genitical Recombination)
Dosage And administration of the intervention : 5mg/kg in a total volume of 100ml, div, every 2 week
Control intervention name : Isotonic sodium chloride solution
INN of the control intervention : -
Dosage And administration of the control intervention : 100ml, div
Kiyoshi SaitoMasazumi Fujii, Masao Kobayakawa, Akihiro Inano, Jun Sakuma, Taku Sato, Akio Morita, Mitsuhiro Hasegawa, Takafumi Mitsuhara, Takashi Tamiya, Takeo Goro, Shigeru Yamaguchi, Hirofumi Nakatomi, Soichi Oyapending1864BOTH60Japan
2ChiCTR18000160402018-05-092018-05-08Clinical efficacy of Bevacizumab in the treatment of Type II NeurofibromatosisClinical efficacy of Bevacizumab in the treatment of Type II Neurofibromatosis Type II NeurofibromatosisCase series:Bevacizumab therapy;Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University, School of MedicineNULLRecruiting6BothCase series:30;China
3NCT01767792May 15, 20137/1/2013Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular SchwannomasOpen-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or RadiationNeurofibromatosis Type 2;Progressive Vestibular SchwannomasDrug: BevacizumabUniversity of Alabama at BirminghamGenentech, Inc.Active, not recruiting6 YearsN/AAll22Phase 2United States
4NCT01661283September 20127/8/2012SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath TumorsPhase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath TumorsMalignant Peripheral Nerve Sheath Tumors;MPNST;SarcomaDrug: everolimus;Drug: bevacizumabSarcoma Alliance for Research through CollaborationNovartis Pharmaceuticals;Genentech, Inc.;United States Department of DefenseCompleted18 YearsN/AAll25Phase 2United States
5NCT01552434March 16, 20127/3/2012Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseA Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsAdvanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland NeoplasmBiological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic AcidM.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingN/AN/AAll216Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01207687October 20101/9/2010Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular SchwannomaVestibular Schwannoma;Neurofibromatosis Type 2Biological: bevacizumab;Other: laboratory biomarker analysis;Procedure: quality-of-life assessmentNational Cancer Institute (NCI)NULLCompleted12 YearsN/AAll14Phase 2United States
7NCT01125046July 20107/5/2010Bevacizumab in Treating Patients With Recurrent or Progressive MeningiomasPhase II Trial of Bevacizumab in Patients With Recurrent or Progressive MeningiomasAcoustic Schwannoma;Adult Anaplastic Meningioma;Adult Ependymoma;Adult Grade I Meningioma;Adult Grade II Meningioma;Adult Meningeal Hemangiopericytoma;Adult Papillary Meningioma;Neurofibromatosis Type 1;Neurofibromatosis Type 2;Recurrent Adult Brain TumorBiological: bevacizumabNorthwestern UniversityNULLUnknown status18 YearsN/AAll50Phase 2United States